home / endocrinology / 2019
Therapeutic Area
2019
Poster
A Randomized-Withdrawal, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Selective Glucocorticoid Receptor Antagonist, Relacorilant, in Patients With Cushing Syndrome (GRACE Study)
Annual Meeting of The Endocrine Society
2019
PosterSustained Clinical Improvement After Discontinuation of Mifepristone: Unexpected Remission of Hypercortisolism
Annual Meeting of The Endocrine Society
2019
PosterAnticipating Hypokalemia in Patients With ACTH-Dependent Cushing Syndrome Treated With Mifepristone: Utilization of Cortisol and ACTH Levels to Identify At-Risk Patients
Annual Meeting of The Endocrine Society
2019
PosterTumor Shrinkage With Preoperative Relacorilant Therapy in Two Patients With Cushing Disease due to Pituitary Macroadenomas
Annual Meeting of The Endocrine Society
2019
PosterImprovement in Muscle Strength and Psychiatric Symptoms in a Patient With Persistent Cushing Disease Treated With Mifepristone
American Association of Clinical Endocrinology
2019
PosterClinical Consequences of an Untreated Cortisol-Producing Adrenal Adenoma: A 10-Year History
American Association of Clinical Endocrinology
2019
PosterPrevalence of Hypercortisolism in Patients With Type 2 Diabetes Mellitus With Incidentally Found Adrenal Adenomas: An Interim Analysis
American Association of Clinical Endocrinology
2019
PosterMifepristone Provides Beneficial Clinical Improvement in Two Cushing Disease Cases in a Community Endocrinology Practice
American Association of Clinical Endocrinology
2019
PosterEfficacy and Safety of the Selective Glucocorticoid Receptor Modulator, Relacorilant (up to 400 mg/day), in Patients With Endogenous Hypercortisolism: Results From an Open-Label Phase 2 Study
American Association of Clinical Endocrinology
2019